RecruitingPhase 2NCT07705737

Rademikibart IV for Acute Asthma and COPD Exacerbation

A Phase 2, Open-Label, Single-Arm Trial to Evaluate IV Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Asthma and or COPD With Type 2 Inflammation

Sponsor

Connect Biopharm LLC

Enrollment

40 participants

Start Date

Aug 21, 2026

Study Type

INTERVENTIONAL

Conditions

Asthma Acute COPD Exacerbation Acute

Summary

A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Rademikibart for people with asthma acute and copd exacerbation acute. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.